-
Innovation
from patented BM technology
To
Regeneration
of surgical tissue and critical care management!
ZR MedTech
The Team
Yanyan Wang
-
Chairman of the Board and Chief Executive Officer
ZR MedTech
Innovation to Regeneration
We deliver innovative excellence for surgeons to regenerate patients’ life.
15 years ago, I was challenged by a surgeon that there was no real long-term solution for treating tissue defects. Many patients suffering from recurrence or no effective clinical solutions for biodegraded tissue restoration postoperatively. In these years, we continued to develop our technology encouraged by our friends and partners from clinic and scientific works. We learned to understand deeper of biology and respect of it. Subsequent iteration of our technology was never been paused. Now, our technology is being able to help millions of people recovering from diseases, and we are still on the way of understanding unknown, and providing new solutions for the same question.
We deliver innovative excellence for surgeons to regenerate patients’ life.
We only bring product excellence.
— Dr. Yanyan Wang,
Founder of ZR Medtech
Yang Sun, PhD
Innovative Business & BD Director
Wenyue Chen, MSc
Fundamental Research & Patent Deputy Director
Sishi Chen, MSc
Regulatory Affairs Deputy Director
Junjun Cui, MSc
Sales Director
Meibiao Zhao, MSc
Chief Engineer
Zhao He
Marketing Director
Xiao Chen
R&D Director
Liangliang Gu
Clinical Affair Director
Yechen Wang
Legal & Compliance Senior Manager
Huiping Xiong
Financial Director
Ziwei Wu
HR Senior Manager
Our
History
2015
ZR MedTech was established.
Basement membrane Technology(ExceBM™)was born in the laboratory.
2016
ZR MedTech Regenerative Medicine Research Center was
constructed.
Construction of small scale production line had been completed.
2018
ExceReg™ Biological Surgical
Graft launched a multi-center
clinicaLRCT.
ExceReg™ Biological Surgical Graft listed of the "Innovation Approval Procedure for Medical Devices" by NMPA.
2019
ExceFil™ Dural (Spinal) Graft launched a multi-center RCT.
2020
Construction of large scale production line had been
completed.
Soft tissue graft (Oral) launched a multi-center RCT.
2021
ExCeReg ™ Biological Surgical
Graft certification was approved
by NMPA.
Pelvic Graft multi-center RCT launched.
2022
ExceFil™ Dual (Spinal) Graft
certification approved by NMPA.
Pelvic Graft listed of the “innovation Approval Procedure for Medical Devices" by NMPA.
2023
ZR MedTech R&D (Shanghai)
successfully constructed.
Staple line reinforcement and
wound dressing multi-center clinical RCT launched.
Incisional Ventral hernia graft
multi-center RCT launched.
2 products were submitted to FDA registration.
Our
Mission
Leader of Surgical Tissue Reconstruction and Critical Management
Innovation to
Regeneration
-
ZR MedTech Founded in 2015
-
Currently own 5 PCT Patents、2 NMPA Class lll Medical Device Registration Certificates、2 “Innovative Green Pathway for Medical Devices” by NMPA
-
30+ pipeline supported by strong R&D capacity
-
Intelligent Manufactory with ISO13485 & MDSAP
5500m2
Taicang
2200m2
Shanghai R&D Center
100000m2
Shanghai One-Site Center (2025)
